A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch
Edward L. Barnes(University of North Carolina at Chapel Hill), Maia Kayal(Icahn School of Medicine at Mount Sinai), Raymond K. Cross(University of Maryland, Baltimore), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Jennifer I. Barr(University of North Carolina at Chapel Hill), Laura E. Raffals(Mayo Clinic), Taha Qazi(Cleveland Clinic), Chelsea Anderson(University of North Carolina at Chapel Hill), Peter Higgins(Michigan Medicine), Millie D. Long(University of North Carolina Health Care), Poonam Beniwal‐Patel(Medical College of Wisconsin), Hans Herfarth(University of North Carolina at Chapel Hill), Michael D. Kappelman(University of North Carolina at Chapel Hill), Sam S. Chang(Memorial Sloan Kettering Cancer Center), Parakkal Deepak(Washington University in St. Louis)
Cited by 2
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Burden of Gastrointestinal Disease in the United States: 2012 Update
|Gastroenterology|2012|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018
|Gastroenterology|2018|1.7k